BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8021734)

  • 1. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
    Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
    J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.
    Maksymiuk AW; Jett JR; Earle JD; Su JQ; Diegert FA; Mailliard JA; Kardinal CG; Krook JE; Veeder MH; Wiesenfeld M
    J Clin Oncol; 1994 Jan; 12(1):70-6. PubMed ID: 8270988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Dalesio O; McVie GJ; Kirkpatrick A; Postmus PE; Burghouts JT; Bakker W; Koolen MG; Vendrik CP; Roozendaal KJ
    J Clin Oncol; 1993 Jul; 11(7):1230-40. PubMed ID: 8391065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
    Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
    J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Stewart CF; Griffin JP
    Cancer Chemother Pharmacol; 1992; 31(2):161-6. PubMed ID: 1333371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
    Clark PI; Cottier B
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):36-9. PubMed ID: 1336898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
    Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
    Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.